| UNIQURE N.V. EO -,05 |
| Niederlande |
| Gesundheit |
| NL0010696654 / A1XDTV |
| UQ1 (Frankfurt) / QURE (NASDAQ) |
| FRA:UQ1, ETR:UQ1, UQ1:GR, NASDAQ:QURE |
| - |
| https://www.uniqure.com/ |
|
uniQure N.V. is a biopharmaceutical company specializing in the development of gene therapies for patients with severe genetic and other devastating diseases. Its primary focus lies in leveraging aden..
>Volltext.. |
| 1067.35 Mio. EUR |
| 928.59 Mio. EUR |
| 13.31 Mio. EUR |
| -149.52 Mio. EUR |
| -198.74 Mio. EUR |
| -3.71 EUR |
| 449.34 Mio. EUR |
| 504.61 Mio. EUR |
| -130.13 Mio. EUR |
| 6.9 |
| -47.72% |
| 6.84% |
| - |
| - |
| - |
| - |
| UNIQURE |
| 19.02.26 |